Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
Sales of Ozempic are booming.
Maker Novo Nordisk on Friday raised its sales and profit outlook for the year because of higher-than-expected U.S. prescription volumes for Ozempic, the diabetes drug that is used off-label for weight loss.
Denmark-based Novo also cites gross-to-net sales adjustments
A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.